
The recommendation is backed by data from the phase 3 LITESPARK-011 trial.
Rohit Jain, MD, Moffitt Cancer Center, discusses risk status and other factors he considers in treatment selection for patients with advanced renal cell carcinoma (RCC).
Note: this interview was filmed before the